Inoviq Ltd has released a press release.
BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Inoviq
- BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference
- BARD1 Launches its RUO EXO-NET Product
- Appendix 4C and Quarterly Activities Report
- Positive Results from the BARD1 Autoantibody Assay
- BARD1 Signs Option Agreement for Type 3C Diabetes Test
Later from Inoviq
- Update on Legal Proceedings
- BARD1 Autoantibody Test Results for Ovarian Cancer Published
- BARD1 Investor Presentation
- BARD1 $15m Placement to Accelerate Cancer Diagnostic Program
- Updated Investor Presentation
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq